LACTOLOGY FOUNDATION

Drugs in ATC class A03AB53 are fixed combinations containing oxyphenonium, a quaternary ammonium anticholinergic used as a gastrointestinal and biliary antispasmodic, and they pose relevant systemic anticholinergic risks with a generally unfavourable safety profile in breastfeeding. Because safer antispasmodic alternatives exist in lactation, oxyphenonium‑containing combinations are usually best avoided in nursing mothers, particularly with newborn or preterm infants.medpedia.framar+3

Pharmacological class and composition

ATC A03AB53 comprises combinations based on oxyphenonium (usually oxyphenonium bromide) with other agents used for functional gastrointestinal or biliary spasm. Oxyphenonium is a synthetic anticholinergic, a quaternary ammonium compound that selectively blocks peripheral muscarinic receptors in smooth muscle and exocrine glands.drugbank+1

The combinations are classified within A03A “Drugs for functional bowel disorders”, subgroup A03AB “Synthetic anticholinergics, quaternary ammonium compounds”, and are marketed mainly as oral tablets or drops for spasm relief.medpedia.framar+1

Mechanism of action

Oxyphenonium acts as a competitive antagonist at muscarinic M‑receptors, reducing the effect of acetylcholine on smooth muscle in the gastrointestinal tract and biliary system. This leads to decreased gastrointestinal propulsive motility, relaxation of smooth muscle and reduced gastric acid secretion, as well as diminished salivary and bronchial secretions.drugbank+1

As a permanently charged quaternary ammonium compound, oxyphenonium has limited penetration through the blood–brain barrier compared with tertiary anticholinergics, so central nervous system (CNS) effects are usually less pronounced at therapeutic doses, although not absent in overdose.uomus+2

Therapeutic indications

According to the Bulgarian pharmacological description, oxyphenonium is indicated for smooth muscle spasm of internal organs and is used for biliary colic in cholelithiasis, cholecystitis, cystitis, renal colic and dysmenorrhoea. In wider references it is described as an adjunctive antispasmodic in gastric and duodenal ulcer disease and for relief of visceral spasms, including irritable bowel syndrome–type complaints.medpedia.framar+1

Within combination products (A03AB53), oxyphenonium may be paired with analgesics or other spasmolytics to enhance symptomatic relief of acute abdominal or biliary pain, although exact co‑components vary by national product.drugbank+1

Dosage and administration

The Framar monograph emphasizes that dosage regimens for oxyphenonium in combination products should be determined by a physician, and recommends medical consultation before use. Preparations are prescription‑only and are usually administered orally before meals, with dose and frequency tailored to indication, severity of spasm, age and comorbidities.mims+1

In clinical practice, treatment should be for the shortest duration needed to control symptoms, with regular reassessment, especially in patients at higher risk of anticholinergic adverse effects (elderly, cardiovascular disease, urinary outflow obstruction).emedicine.medscape+2

General toxicity and adverse effects

The Framar entry lists a typical anticholinergic adverse‑effect profile: mydriasis, photophobia, vomiting, constipation, initial bradycardia followed by tachycardia and arrhythmia, flushing and dryness of the skin, urinary disturbances, difficulty in swallowing and speech, thirst and reduced bronchial secretion. These manifestations reflect peripheral muscarinic blockade in ocular, cardiac, gastrointestinal, genitourinary and secretory systems.uomus+2

Systemic anticholinergic toxicity from oxyphenonium or other antimuscarinics is characterized by the classic toxidrome—hyperthermia, dry mucous membranes and skin, urinary retention, mydriasis with blurred vision, flushed skin and altered mental status (“anticholinergic syndrome”). Severe cases may progress to agitation, delirium, seizures, arrhythmias and circulatory instability requiring intensive care and specific antidotal therapy.youtubeemedicine.medscape+1

Contraindications and precautions

The Bulgarian text states that oxyphenonium should not be used in patients with hypersensitivity to the drug or to any component of the combination product. Other authoritative monographs list additional contraindications and cautions typical for anticholinergics: children and the elderly, benign prostatic hyperplasia with urinary retention risk, acute myocardial infarction, cardiac failure, hypertension, thyrotoxicosis, fever, and pregnancy and lactation.mims+2

Given the quaternary anticholinergic mechanism, oxyphenonium‑containing drugs should be used cautiously or avoided in patients with narrow‑angle glaucoma, paralytic ileus, severe ulcerative colitis, obstructive uropathy or tachyarrhythmias because of potential exacerbation of these conditions.emedicine.medscape+2

Acute overdose and management

Overdose with oxyphenonium or other potent anticholinergics produces a full anticholinergic toxidrome with peripheral and central manifestations. Management priorities include airway protection, support of breathing and circulation, continuous cardiac and pulse monitoring, and early gastrointestinal decontamination with activated charcoal when appropriate and in consultation with toxicology services.youtubeuomus+1

Benzodiazepines are recommended for seizures or marked agitation, while serious conduction disturbances or wide QRS complexes on ECG may respond to sodium bicarbonate, and ventricular arrhythmias can be treated with lidocaine. Physostigmine salicylate is the specific antidote capable of reversing central and peripheral anticholinergic effects, but due to its own toxicity risk it should be reserved for severe, well‑documented anticholinergic poisoning and used only under expert guidance.uomus+1

Use in pregnancy (brief)

Available references categorize oxyphenonium as a drug with insufficient human pregnancy data and adverse effects in animal studies, and therefore advise against its routine use during pregnancy unless clearly needed and after risk–benefit assessment. Because the indication is usually symptomatic and alternatives exist, most product information recommends avoiding oxyphenonium combinations in pregnancy.medex+1

Lactation: transfer into milk

Direct quantitative data on oxyphenonium levels in human milk are scarce, but at least one product information document explicitly states that oxyphenonium bromide is excreted into breast milk and is harmful to the child’s health, and therefore its use in breastfeeding mothers is not recommended. As a quaternary ammonium anticholinergic with systemic activity, some transfer into milk is plausible, though the proportion is unknown and may vary with dose, route and maternal pharmacokinetics.profarma+1

Because the drug is used systemically and not as a topical local preparation, repeated maternal dosing could lead to sustained low‑level infant exposure, particularly in exclusively breastfed infants and those with immature renal and hepatic elimination.who+1

Lactation: potential infant effects

Given the mechanism of action, the principal concern in breastfed infants is systemic anticholinergic exposure leading to:

• Decreased gastrointestinal motility and constipation, with possible feeding intolerance or ileus in vulnerable neonates.who+1
• Urinary retention, dry mucous membranes and impaired sweating, which increase risk of dehydration and hyperthermia, particularly in hot environments or during intercurrent illness.youtubewho+1

At higher relative exposures, CNS anticholinergic effects such as irritability, restlessness or, conversely, sedation and impaired arousal could theoretically occur, although quaternary structure limits but does not exclude CNS penetration in very young infants. There are no robust published case series specifically describing oxyphenonium‑induced toxicity in breastfed infants, so risk estimates remain extrapolated from pharmacology and experience with similar anticholinergics.emedicine.medscape+2

Lactation: effect on milk production

Anticholinergic drugs can reduce secretions and may potentially interfere with prolactin or oxytocin‑mediated reflexes, although evidence is limited and inconsistent. In theory, strong systemic muscarinic blockade might blunt the neurohormonal response to suckling or indirectly reduce milk supply by causing maternal dehydration and illness, but such effects have not been well quantified for oxyphenonium.mayoclinic+1

Nevertheless, authoritative breastfeeding guidance notes that some medicines may adversely affect milk production or let‑down, and emphasizes individualized assessment and monitoring when anticholinergic regimens are necessary in lactating women.mayoclinic+1

Lactation safety assessment

Key points for lactation risk assessment of A03AB53 products are:

• Oxyphenonium is a potent systemic anticholinergic with recognized adverse‑effect profile and specific warning against use during lactation in at least one product monograph.profarma+2
• The indication (gastrointestinal or biliary spasms, dysmenorrhoea) is generally not life‑threatening, and alternative antispasmodics with more favourable breastfeeding data exist.sps+1

National specialist guidance on gastrointestinal antispasmodics in breastfeeding identifies hyoscine butylbromide, propantheline, peppermint oil, mebeverine and alverine as preferred options, while oxyphenonium is not listed among recommended agents. Taken together, these considerations support classifying oxyphenonium combinations as “generally not recommended” during breastfeeding, especially for neonates and preterm infants.sps+2

Practical lactation recommendations

For a breastfeeding mother who requires treatment for functional bowel spasm, biliary colic or related indications:

• Avoid routine use of oxyphenonium‑containing combinations (A03AB53) during lactation, particularly in the early postpartum period and for exclusively breastfed or vulnerable infants.profarma+2
• Consider alternative antispasmodics with better lactation data such as hyoscine butylbromide, propantheline, peppermint oil, mebeverine or alverine, in line with specialist breastfeeding medicine recommendations and local availability.sps+1

If use of oxyphenonium in combination is nonetheless considered essential (for example, lack of alternatives or inadequate response):

• Use the lowest effective dose for the shortest possible duration and avoid repeated or chronic courses.mims+2
• Monitor the breastfed infant for signs of anticholinergic effects (poor feeding, constipation, reduced wet nappies, unusual sleepiness or irritability, fever without clear cause), and seek medical review immediately if these occur.whoyoutubeuomus
• For high‑risk infants (premature, low birth weight, significant comorbidities), temporary interruption of breastfeeding with expressed‑and‑discarded milk during maternal therapy may be considered, with individualized specialist advice.mayoclinic+1

Summary for clinical use

Oxyphenonium‑containing antispasmodic combinations (A03AB53) are effective for smooth muscle spasm of the gastrointestinal and genitourinary tract, but carry the usual spectrum of anticholinergic toxicity, including ocular, cardiac, gastrointestinal and urinary adverse effects, and risk of serious anticholinergic syndrome in overdose. In breastfeeding, available product information and comparative guidance indicate that oxyphenonium is excreted into milk and is not recommended because of potential infant harm and the availability of safer antispasmodic alternatives.medpedia.framar+1youtubeprofarma+3